Clinical trials: Precocious Puberty, Central
Precocious Puberty, Central
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
- Trial name
- NCT02452931
- Testing
- Leuprolide Acetate 45 mg
- Where
- 20 sites in United States, Argentina and 4 more
- Volunteers
- 64 people
- Sponsor
- Tolmar Inc.
Central Precocious Puberty
Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty
A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty
- Trial name
- NCT03316482
- Testing
- Leuplin DPS 11.25mg
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Jin Soon Hwang
Central Precocious Puberty
Markers of Pubertal Suppression During Therapy for Precocious Puberty
The best way to measure whether treatment of children with central precocious puberty is working is to do a hormone stimulation test (leuprolide stimulation test) that requires injection of a medication and multiple blood draws…
- Trial name
- NCT02006680
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Central Precocious Puberty
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty.
- Trial name
- NCT01467882
- Testing
- Triptorelin
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 44 people
- Sponsor
- Debiopharm International SA
Precocious Puberty, Central
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate
- Trial name
- NCT02974270
- Testing
- Leuprolide
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Kyungpook National University Hospital
Central Precocious Puberty
Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with…
- Trial name
- NCT02920515
- Testing
- Triptorlin or Leuprorelin, Zhibo dihuang pills, Dabu ying pills
- Volunteers
- 740 people
- Sponsor
- Ruijin Hospital
Central Precocious Puberty
The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty
The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.
- Trial name
- NCT01634321
- Testing
- Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Central Precocious Puberty
Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children
The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty.
- Trial name
- CPP-EDG 01 (NCT00438217)
- Testing
- Triptorelin (GnRH agonists), Leuprolide (GnRH agonists)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa